FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

Fate Therapeutics4 个研究点分布在 1 个国家目标入组 37 人开始时间: 2019年2月15日最近更新: 2023年5月1日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Fate Therapeutics
入组人数: 37
试验地点: 4
主要终点: The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Diagnosis of the following, as per Regimen Cohort:
•1A. Regimen A: FT500 Monotherapy (Dose Escalation): An advanced solid tumor malignancy, including lymphoma, in a participant who has failed or refused available FDA-approved therapies and is now a candidate for salvage therapy.
•1B. Regimen B and BB (Dose Escalation): FT500 (+ IL-2, Regimen BB only) + ICI: An advanced solid tumor malignancy, including lymphomas, that has progressed on treatment with at least one ICI (ie, nivolumab, pembrolizumab or atezolizumab), in a participant who has also failed or refused other available approved therapies and is now a candidate for salvage therapy.
•1C. Regimen B(Dose Expansion): FT500 (+ IL-2, Regimen BB only) + ICI An advanced solid tumor malignancy or lymphoma in a participant with disease relapse or progression on an ICI (nivolumab, pembrolizumab, or atezolizumab) in an approved indication per the respective USPI.
•Willingness to provide informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
•Age >18 years old at the time of signing the ICF.
•Presence of measurable disease by iRECIST or RECIL criteria, assessed before the start of lympho-conditioning and within 28 days prior to Day
•Contraceptive use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•5a. Female participants: Women of childbearing potential (WOCBP) must use a highly effective form of contraception from the screening visit until at least 12 months after the final dose of CY, at least 4 months after the final dose of FT500, at least 4 months after the final dose of pembrolizumab, and at least 5 months after the final dose of nivolumab or atezolizumab, whichever is latest.
•5b. Male participants: Males must be sterile (biologically or surgically) or use a highly effective method of contraception from the screening visit until at least 14 months after the final dose of CY, at least 6 months after the final dose of FT500, at least 6 months after the final dose of pembrolizumab, and at least 7 months after the final dose of nivolumab or atezolizumab, whichever is latest.
•Willingness to comply with study procedures through the planned study duration. For patients with >1 measurable lesion, agreement to undergo a biopsy from a safely accessible site per Investigator assessment for exploratory biomarker assessments.
•Provision of signed and dated ICF to agree to participate, at time of withdrawal or completion of this study, in Fate Therapeutics' long-term, non-interventional, observational study, FT-003.

排除标准

•All participants:
•Females who are pregnant or breastfeeding.
•ECOG performance status ≥
•Evidence of insufficient organ function as determined by any one of the following: 3a. Neutrophils <1000/µL or platelets <75,000/µL. 3b. Estimated creatinine clearance <50 mL/minute (Cockcroft-gault). 3c. Total bilirubin >2 x upper limit normal (ULN) with the exception of participants with Gilbert's Syndrome or known liver metastases.
•3d. Aspartate aminotransferase (AST) >3 x ULN, or alanine aminotransferase (ALT) >3 x ULN. For participants with known liver metastases, AST or ALT >5 x ULN.
•3e. Oxygen saturation <90% on room air. 3f. Left ventricular ejection fraction (LVEF) <40% (eg by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan).
•4.Receipt of any biological therapy, chemotherapy, or radiation (except palliative radiation) within 2 weeks prior to Day
•Participants in Regimen B currently taking an ICI must interrupt ICI dosing at least 2 weeks prior to Day
•CNS metastases that have not been treated; or treated CNS metastases that have not been stable for at least 4 weeks.
•Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first study medication; or the presence of unstable angina or congestive heart failure of New York Heart Association grade 2 or higher.
•Currently receiving or likely to require systemic immunosuppressive therapy (eg, prednisone >5 mg daily) for any reason from Day -7 to Day
•Uncontrolled infections.
•Known allergy to the following FT500 components: Albumin (Human) or DMSO.
•Presence of any medical or social issues that are likely to interfere with study conduct, or may cause increased risk to participant.
•Any medical condition or clinical laboratory abnormality that, per Investigator or Medical Monitor judgement, precludes safe participation in and completion of the study, or that could affect compliance with protocol conduct or interpretation of results. Participants who have had prior receipt of a Fate Therapeutics investigational human iPSC product may be eligible for the study with approval from the Medical Monitor.
•Additional Exclusion Criteria for Regimen B: FT500 + ICI:
•Participants who experienced an ICI-related adverse reaction that resulted in discontinuation of the ICI.
•Presence or history of autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma, Crohn's disease, ulcerative colitis), except for participants with isolated vitiligo, atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and controlled thyroid disease.
•Participants who have received an allograft organ transplant.

研究组 & 干预措施

FT500 Monotherapy

Experimental

FT500 administered once weekly for 3 weeks as a monotherapy

干预措施: FT500 (Drug)

FT500 Monotherapy

Experimental

FT500 administered once weekly for 3 weeks as a monotherapy

干预措施: Cyclophosphamide (Drug)

FT500 Monotherapy

Experimental

FT500 administered once weekly for 3 weeks as a monotherapy

干预措施: Fludarabine (Drug)

FT500 in Combination with Immune Checkpoint Inhibitor

Experimental

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

干预措施: FT500 (Drug)

FT500 in Combination with Immune Checkpoint Inhibitor

Experimental

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

干预措施: Nivolumab (Drug)

FT500 in Combination with Immune Checkpoint Inhibitor

Experimental

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

干预措施: Pembrolizumab (Drug)

FT500 in Combination with Immune Checkpoint Inhibitor

Experimental

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

干预措施: Atezolizumab (Drug)

FT500 in Combination with Immune Checkpoint Inhibitor

Experimental

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

干预措施: Cyclophosphamide (Drug)

FT500 in Combination with Immune Checkpoint Inhibitor

Experimental

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

干预措施: Fludarabine (Drug)